查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1954306

特发性血小板减少紫斑症治疗市场分析及至2035年预测：按类型、产品、服务、技术、应用、最终用户、设备、流程、解决方案和给药途径划分

Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 388 Pages | 商品交期: 3-5个工作天内

价格
简介目录

特发性血小板减少紫斑症)治疗市场预计将从 2024 年的 6.746 亿美元成长至 2034 年的 10.576 亿美元，复合年增长率约为 6.1%。 ITP 治疗市场涵盖旨在治疗 ITP 的特发性血小板减少紫斑症治疗方法，ITP 是一种以血小板数量低和出血风险增加为特征的疾病。该市场包括皮质类固醇、免疫球蛋白、血小板生成素促效剂和新型生物製药。疾病认知度的提高、生物製药的进步以及自体免疫疾病的增加正在推动市场成长。市场关注的重点是透过个人化医疗和创新治疗方法来改善患者的治疗效果。

特发性血小板减少紫斑症(ITP) 治疗市场正经历着蓬勃发展，这主要得益于治疗研究方法的进步和疾病认知度的提高。药物治疗处于领先地位，其中皮质类固醇和血小板生成素受体促效剂是主要细分市场。这些治疗方法对于控制患者的血小板数量至关重要。免疫球蛋白仍然是第二大细分市场，能够快速改善急性期患者的血小板数。生物製药市场由于针对特定免疫路径的单株抗体的有效性而发展迅速。在该细分市场中，抗D免疫球蛋白细分市场，特别是针对Rh阳性患者的抗D免疫球蛋白，已成为重要的市场贡献者。此外，对个人化医疗的日益重视正在推动客製化治疗方法的开发，以改善治疗效果。联合治疗的兴起，即整合多种治疗方法以提高患者疗效并降低復发率，为相关人员提供了丰厚的机会。

市场区隔
类型 慢性特发性血小板减少紫斑症，急性特发性血小板减少紫斑症
产品 皮质类固醇、静脉注射免疫球蛋白（IVIg）、抗D免疫球蛋白、血小板生成素促效剂、单株抗体、免疫抑制剂
服务 病人支持服务、咨询服务和治疗监测
科技 生物製药、小分子药物、基因疗法
目的 医院、专科诊所和研究机构
最终用户 医疗保健提供者、患者和製药公司
装置 输液帮浦、注射器
流程 药物研发、临床试验、监理核准及生产
解决方案 治疗方案、诊断方案
给药途径 口服、静脉注射、皮下注射

特发性血小板减少紫斑症(ITP) 治疗市场的特征是主要企业之间的市场份额动态变化。创新治疗方法和生物相似药的推出导致定价策略竞争日益激烈。在生物技术进步和对疾病机制更深入了解的推动下，新产品经常上市。市场正经历着向个人化医疗的策略转型，以提高治疗效果和患者预后。 ITP 治疗市场竞争异常激烈，主要企业透过策略联盟和併购争夺主导。监管影响至关重要，因为北美和欧洲严格的核准流程决定企业的市场准入和扩张。对竞争对手的比较分析表明，各公司都专注于研发投入和临床试验进展。新兴市场由于医疗保健支出不断增长和公众意识的提高，蕴藏着巨大的成长潜力。随着数位医疗技术和以患者为中心的理念塑造未来市场趋势，市场格局正在改变。

主要趋势和驱动因素：

由于生物技术和个人化医疗的进步，特发性血小板减少紫斑症(ITP) 治疗市场正在快速发展。主要趋势包括新型生物製药和标靶治疗的研发，这些疗法疗效更佳，副作用更少。这些创新正在改善患者的治疗效果，并扩大 ITP 的治疗选择。 ITP 的认知度和诊断率的提高也对市场产生影响，推动患者数量成长，并增加对有效治疗方法的需求。此外，製药公司与研究机构之间的合作正在加速药物发现和开发的步伐，从而创造出竞争激烈且充满活力的市场环境。监管部门对孤儿药的支持和快速核准流程进一步促进了市场成长。新兴市场蕴藏着许多机会，这些地区的医疗基础设施正在发展，人们对罕见疾病的认识也不断提高。投资这些地区的公司可以充分利用尚未开发的潜力，并扩大其全球商业版图。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 慢性特发性血小板减少紫斑症
    • 急性特发性血小板减少紫斑症
  • 市场规模及预测：依产品划分
    • 皮质类固醇
    • 静脉注射免疫球蛋白（IVIg）
    • 抗D免疫球蛋白
    • 血小板生成素受体促效剂
    • 单株抗体
    • 免疫抑制剂
  • 市场规模及预测：依服务划分
    • 病人支援服务
    • 咨询服务
    • 治疗监测
  • 市场规模及预测：依技术划分
    • 生物製药
    • 小分子药物
    • 基因治疗
  • 市场规模及预测：依应用领域划分
    • 医院
    • 专科诊所
    • 研究所
  • 市场规模及预测：依最终用户划分
    • 医疗保健提供者
    • 病人
    • 製药公司
  • 市场规模及预测：依设备划分
    • 点滴帮浦
    • 注射器
  • 市场规模及预测：依製程划分
    • 药物研发
    • 临床试验
    • 监管部门核准
    • 製造业
  • 市场规模及预测：按解决方案划分
    • 治疗方案
    • 诊断解决方案
  • 市场规模及预测：依管理途径
    • 口服
    • 静脉
    • 皮下

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Rigel Pharmaceuticals
  • Argenx
  • Dova Pharmaceuticals
  • Hansa Biopharma
  • Principia Biopharma
  • Kezar Life Sciences
  • Immunovant
  • UCB
  • Achillion Pharmaceuticals
  • Genentech
  • Novimmune
  • Momenta Pharmaceuticals
  • Bioverativ
  • Sobi
  • CSL Behring
  • Grifols
  • Octapharma
  • Kamada
  • Apellis Pharmaceuticals
  • Akari Therapeutics

第九章：关于我们

简介目录
Product Code: GIS26461

Idiopathic Thrombocytopenic Purpura Therapeutics Market is anticipated to expand from $674.6 million in 2024 to $1,057.6 million by 2034, growing at a CAGR of approximately 6.1%. The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market encompasses treatments aimed at managing ITP, a disorder characterized by low platelet counts leading to bleeding risks. This market includes corticosteroids, immunoglobulins, thrombopoietin receptor agonists, and novel biologics. Increasing awareness, advancements in biologics, and a rise in autoimmune disorders drive market growth. The focus is on personalized medicine and improving patient outcomes through innovative therapies.

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is experiencing dynamic growth, propelled by advancements in treatment methodologies and increased disease awareness. The pharmacological therapy segment is at the forefront, with corticosteroids and thrombopoietin receptor agonists leading as top-performing sub-segments. These treatments are crucial in managing platelet counts in patients. Immunoglobulins follow as the second highest performing sub-segment, offering rapid platelet count improvement in acute cases. The biologics segment is gaining momentum, driven by the efficacy of monoclonal antibodies in targeting specific immune pathways. Within this segment, the anti-D immunoglobulin sub-segment is emerging as a significant contributor, particularly for Rh-positive patients. Additionally, the increasing focus on personalized medicine is augmenting the development of tailored therapeutic options, enhancing treatment outcomes. The market is also witnessing a shift towards combination therapies, integrating multiple treatment modalities to improve patient response and reduce relapse rates, thereby presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeChronic Idiopathic Thrombocytopenic Purpura, Acute Idiopathic Thrombocytopenic Purpura
ProductCorticosteroids, Intravenous Immunoglobulins (IVIg), Anti-D Immunoglobulins, Thrombopoietin Receptor Agonists, Monoclonal Antibodies, Immunosuppressants
ServicesPatient Support Services, Consultation Services, Therapeutic Monitoring
TechnologyBiologics, Small Molecule Drugs, Gene Therapy
ApplicationHospitals, Specialty Clinics, Research Institutes
End UserHealthcare Providers, Patients, Pharmaceutical Companies
DeviceInfusion Pumps, Syringes
ProcessDrug Development, Clinical Trials, Regulatory Approval, Manufacturing
SolutionsTreatment Solutions, Diagnostic Solutions
ModeOral, Intravenous, Subcutaneous

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is characterized by a dynamic distribution of market share among leading pharmaceutical companies. Pricing strategies are becoming increasingly competitive, influenced by the introduction of innovative therapies and biosimilars. New product launches are frequent, driven by advancements in biotechnology and a growing understanding of disease mechanisms. The market is witnessing a strategic shift towards personalized medicine, which is enhancing treatment efficacy and patient outcomes. Competition in the ITP therapeutics market is intense, with key players vying for dominance through strategic partnerships and mergers. Regulatory influences play a pivotal role, as stringent approval processes in North America and Europe dictate market entry and expansion. Benchmarking against competitors reveals a focus on R&D investments and clinical trial advancements. Emerging markets are showing potential for growth, driven by increased healthcare expenditure and awareness. The landscape is evolving, with digital health technologies and patient-centric approaches shaping future market trajectories.

Geographical Overview:

The Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market is witnessing notable expansion across various regions, each presenting unique growth dynamics. North America stands at the forefront, propelled by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies further accelerates market growth. Europe trails closely, with its emphasis on innovation and strong regulatory frameworks fostering a conducive environment for therapeutic advancements. In the Asia Pacific region, the market is burgeoning, driven by rising healthcare awareness and increasing prevalence of ITP. Emerging economies, such as China and India, are becoming lucrative markets due to their large patient populations and improving healthcare systems. Latin America is also gaining traction, with Brazil and Mexico spearheading investments in healthcare. The Middle East & Africa are witnessing gradual growth. Countries like Saudi Arabia and South Africa are recognizing the importance of enhancing healthcare capabilities, thus presenting new opportunities for market expansion.

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is intricately influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, trade tensions with the US and China are prompting a strategic shift towards bolstering local pharmaceutical capabilities and diversifying supply chains. China's focus on self-reliance is driving investments in biopharmaceutical innovations, while Taiwan's strategic positioning in the semiconductor industry underscores its vulnerability amidst geopolitical frictions. Globally, the parent market of rare disease therapeutics is expanding, driven by increasing awareness and advanced research. By 2035, the ITP market is anticipated to grow through collaborative R&D and strategic regional partnerships. Middle East conflicts, impacting oil prices, indirectly affect global supply chains, influencing manufacturing and logistics costs in the healthcare sector.

Key Trends and Drivers:

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is evolving rapidly, driven by advancements in biotechnology and personalized medicine. Key trends include the development of novel biologics and targeted therapies that offer improved efficacy and reduced side effects. These innovations are enhancing patient outcomes and expanding treatment options for ITP. The market is also influenced by increasing awareness and diagnosis of ITP, leading to a rise in patient numbers and subsequent demand for effective treatments. Additionally, collaborations between pharmaceutical companies and research institutions are accelerating the pace of drug discovery and development, fostering a competitive and dynamic market landscape. Regulatory support and expedited approval processes for orphan drugs are further propelling market growth. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of rare diseases is increasing. Companies investing in these regions can capitalize on untapped potential and expand their global footprint.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Chronic Idiopathic Thrombocytopenic Purpura
    • 4.1.2 Acute Idiopathic Thrombocytopenic Purpura
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Corticosteroids
    • 4.2.2 Intravenous Immunoglobulins (IVIg)
    • 4.2.3 Anti-D Immunoglobulins
    • 4.2.4 Thrombopoietin Receptor Agonists
    • 4.2.5 Monoclonal Antibodies
    • 4.2.6 Immunosuppressants
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Patient Support Services
    • 4.3.2 Consultation Services
    • 4.3.3 Therapeutic Monitoring
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biologics
    • 4.4.2 Small Molecule Drugs
    • 4.4.3 Gene Therapy
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Research Institutes
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Healthcare Providers
    • 4.6.2 Patients
    • 4.6.3 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Infusion Pumps
    • 4.7.2 Syringes
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Drug Development
    • 4.8.2 Clinical Trials
    • 4.8.3 Regulatory Approval
    • 4.8.4 Manufacturing
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Treatment Solutions
    • 4.9.2 Diagnostic Solutions
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Oral
    • 4.10.2 Intravenous
    • 4.10.3 Subcutaneous

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Rigel Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Argenx
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Dova Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Hansa Biopharma
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Principia Biopharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Kezar Life Sciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Immunovant
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 UCB
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Achillion Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Genentech
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Novimmune
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Momenta Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bioverativ
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sobi
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 CSL Behring
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Grifols
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Octapharma
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Kamada
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Apellis Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Akari Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us